IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-02292296.html
   My bibliography  Save this paper

Cost-effectiveness analyses using real-world data: an overview of the literature

Author

Listed:
  • Kevin Bowrin

    (Bayer S.A.S. [France] - Bayer AG [Germany])

  • Jean-Baptiste Briere

    (Bayer AG [Germany])

  • Pierre Lévy

    (LEDa - Laboratoire d'Economie de Dauphine - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres)

  • Aurélie Millier

    (Creativ-Ceutical France - Creativ-Ceutical, Creativ-Ceutical - Creativ-Ceutical SARL)

  • Emilie Clay

    (Creativ-Ceutical France - Creativ-Ceutical, Evaluation des systèmes de soins et santé perçue - Université de la Méditerranée - Aix-Marseille 2)

  • Mondher Toumi

    (Laboratoire de Santé Publique - Université de la Méditerranée - Aix-Marseille 2, Pharmaco-Epidémiologie - Université Bordeaux Segalen - Bordeaux 2 - INSERM - Institut National de la Santé et de la Recherche Médicale, CEReSS - Centre d'études et de recherche sur les services de santé et la qualité de vie - AMU - Aix Marseille Université)

Abstract

No abstract is available for this item.

Suggested Citation

  • Kevin Bowrin & Jean-Baptiste Briere & Pierre Lévy & Aurélie Millier & Emilie Clay & Mondher Toumi, 2019. "Cost-effectiveness analyses using real-world data: an overview of the literature," Post-Print hal-02292296, HAL.
    • Handle: RePEc:hal:journl:hal-02292296
    DOI: 10.1080/13696998.2019.1588737
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Kevin Bowrin & Jean-Baptiste Briere & Laurent Fauchier & Craig Coleman & Aurélie Millier & Mondher Toumi & Emilie Clay & Pierre Levy, 2020. "Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-15, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-02292296. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.